PhotoMedex, Inc.
HCID Member | Medical Devices & Tech
147 Keystone Drive
Montgomeryville, PA 18936 USA
phone: (215) 619-3600
fax: (215) 619-3208
Symbol PHMD
Exchange Nasdaq
Founded 2000
Employees 138
www.photomedex.com
Research Sector Medical Devices & Tech
Summary Description
Laser systems for the treatment of psoriasis and vitiligo.
Management
Jeffrey F. O'Donnell, President and Chief Executive Officer; Dennis McGrath, Chief Financial Officer and Vice President of Finance and Administration; Michael R. Stewart, Chief Operating Officer; Jeffrey L. Levatter, PhD, Chief Technology Officer
Ownership
Financials Mkt Cap :32


* numbers in thousands

Recent Results
Revenues for the third quarter ended September 30, 2006 were $8.3M as compared to revenues for the third quarter ended September 30, 2005 of $7.6M, an increase of 8.8%. XTRAC® procedures billed in the third quarter of 2006 increased 45% from 2005 third-quarter levels.
 
Keywords
Aesthetics, plastic surgery, skin care, j2008b

Comment | Printable Version | Sept. 01, 2008
If you work for PhotoMedex, Inc. and want to update this profile, click here

Description
PhotoMedex develops proprietary excimer laser and fiber-optic systems for treatment of cardiovascular and vascular disease and for dermatological applications such as psoriasis.
Products / Services
The company's XTRAC excimer laser is used for the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma. PhotoMedex's surgical products include a Contact Laser that can cut, coagulate or vaporize tissue. The company also offers a range of laser services in the areas of urology, gynecology, orthopedics and general surgery. With it's acquisition of ProCyte in 2005, PhotoMedex added a line of skin care treatments to its product portfolio.
Technology / Differentiation
The XTRAC 308 nanometer excimer laser is the first FDA-approved laser treatment for psoriais. It is indicated for patients with stable localized mild-to-moderate plaque psoriasis (about 80% of psoriasis cases), especially for patients whose plaques are recalcitrant to topical therapy. By focusing the energy exclusively to the psoriasis plaques, the laser avoids potentially detrimental exposure of normal skin to UVB energy, and with fewer side effects.
Market / Customers
The company will sell directly to dermatologists, plastic and cosmetic surgeons, spas and salons, and through licenses with strategic partners into the consumer market, including its long-term worldwide license agreement with Neutrogena, a Johnson & Johnson company.
Competitors / Substitutes / Alternatives
Candela Corp., Laserscope, Lumenis
Strategy
Domestic XTRAC revenues are generated from per-procedure fees charged to dermatologists. PhotoMedex will soon initiate a direct-to-consumer marketing campaign for the treatment. International XTRAC revenues come from the sales of the equipment through a network of distributors. Since the launch of the treatment in 2000, PhotoMedex has been very active, and successful, in seeking reimbursement approvals. It targets 100% reimbursement compliance in three years. The acquisiton of ProCyte diversified PhotoMedex into the skin care products business. In addtion to increasing distribution for ProCyte's products, PhotoMedex plans to cross-sell its existing product line to ProCyte customers and to use ProCyte's national sales force to market XTRAC.
Funding
Status
In March 2001, the company received FDA clearance to treat vitiligo; in August 2001, FDA clearance to treat atopic dermatitis; and in May 2002, the FDA granted 510(k) clearance to market the XTRAC system for the treatment of leukoderma. The company introduced the XTRAC phototherapy treatment system commercially in the U.S. during the year ended December 31, 2000.


2008-09-07-3603